The UroLift^® Center of Excellence (COE) Program is designed to enhance patient outcomes and experience. Urologists included in the UroLift^® COE Program have achieved a higher level of training with the UroLift^® System and demonstrated a commitment to care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH) or an enlarged prostate.

Our UroLift^® COE designation criteria changed effective January 15, 2021. All those achieving UroLift^® COE designation on or after January 15, 2021 are required to meet the following criteria.

• Completion of the UroLift^® Proficiency Pathway, which is a surgeon training program launched in March 2017 that includes module, didactic and hands-on device training and completing 15 cases;
• Participation in a minimum of two Teleflex Clinical and Medical Affairs-led educational events for initial designation and one Teleflex Clinical and Medical Affairs led educational events per year for redesignation;
• Completion of a minimum of 60 UroLift^® System cases in the 12-month period* prior to submission for designation**; and
• Submission of de-identified pre- and post-procedure patient International Prostate Symptom Score (IPSS) data from a minimum of 30 UroLift^® System cases completed in the 12-month period* prior to submission for designation**, evidencing:
  - A mean improvement in IPSS of at least 40% compared to baseline average;
  - The dates of the pre- and post-procedure assessments; and
  - Any BPH medication used at the time of the pre- and post-procedure assessments.

Those achieving UroLift^® COE designation prior to January 15, 2021 were required to meet the following criteria:

• Completion of the UroLift^® Proficiency Pathway, which is a surgeon training program launched in March 2017 that includes module, didactic and hands-on device training and completing 15 cases;
• Participation in a minimum of two Teleflex Clinical and Medical Affairs-led educational events per year;
• Completion of a minimum of 60 UroLift^® System cases in the 12-month period* prior to submission for designation**; and
• Submission of de-identified pre- and post-procedure patient International Prostate Symptom Score (IPSS) data from a minimum of 30 UroLift^® System cases completed in the 12-month period* prior to submission for designation**, evidencing:
  - A mean improvement in IPSS of at least 40% compared to baseline average.

If a physician does not retain their designation as a UroLift^® COE physician, the physician’s COE designation will be removed and that physician will be reviewed to determine whether they meet the requirements to remain on the Physician Locator. If the physician does not meet the Physician Locator requirements, the physician will be removed from the Physician Locator entirely.

*Please note, in situations where elective procedures were not allowed due to COVID-19, those months will not be included in the 12-month period for designation or re-designation. Therefore, the assessment period may not be consecutive months.

**Excluding cases completed during UroLift^® Proficiency Pathway training

For more information about the Center of Excellence Program please contact uroliftcoe@teleflex.com

‍